Skip to content
10-Q

Quarterly Report

OS THERAPIES INCORPORATED OSTX

0001213900-26-058070

← back to feed
Filed
May 18, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 44.54M sh
Shares Diluted Q1 2026 · Mar 31, 2026 38.67M sh
Shares Diluted Q1 2026 · Mar 31, 2025 21.25M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.56M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.44M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $917.55K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $269.83K
Cash And Equivalents Q1 2026 · Mar 31, 2025 $2.97M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $5.53M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$10.82M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$6.1M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$4.19M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$3.27M
Current Liabilities Q1 2026 · Mar 31, 2026 $16.95M
Current Liabilities Q1 2026 · Dec 31, 2025 $11.76M
Total Liabilities Q1 2026 · Mar 31, 2026 $17.05M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.86M
Current Assets Q1 2026 · Mar 31, 2026 $917.55K
Current Assets Q1 2026 · Dec 31, 2025 $332.91K
Total Assets Q1 2026 · Mar 31, 2026 $7.3M
Total Assets Q1 2026 · Dec 31, 2025 $6.84M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.27
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.18
Eps Basic Q1 2026 · Mar 31, 2026 −$0.27
Eps Basic Q1 2026 · Mar 31, 2025 −$0.18
Sga Expense Q1 2026 · Mar 31, 2026 $2.82M
Sga Expense Q1 2026 · Mar 31, 2025 $3.69M
Rd Expense Q1 2026 · Mar 31, 2026 $7.35M
Rd Expense Q1 2026 · Mar 31, 2025 $1.31M
Net Income Q1 2026 · Mar 31, 2026 −$10.4M
Net Income Q1 2026 · Mar 31, 2025 −$3.88M
Operating Income Q1 2026 · Mar 31, 2026 −$10.17M
Operating Income Q1 2026 · Mar 31, 2025 −$5M